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Abstract. In 80% to 90% of patients with carcinoids, tumor sites can be
detected with [111In-DTPA-D-Phe1]-octreotide scintigraphy. Unexpected,
additional localizations are reported in one-third to two-thirds of pa-
tients. In a group of 52 patients, we analyzed the results of various
combinations of octreotide scintigraphy and conventional imaging. Oct-
reotide scintigraphy, alone or in combination with other imaging modal-
ities, led to the detection of more tumor sites than any combination of
conventional imaging techniques. The combination of octreotide scintig-
raphy, chest radiography, and ultrasonography of the upper abdomen led
to the detection of lesions in all patients in whom they could be
demonstrated by any imaging means, with a sensitivity of 87% in terms of
the number of detected lesions. The calculated cost for this imaging
regimen was higher than for the combination of conventional imaging as
applied in our group. However, the benefit was the detection of at least
one lesion in 11% of patients in whom with conventional imaging no
abnormalities were found. Moreover, if the results from our patient group
were extrapolated to a group of 100 patients, the advantage in terms of the
number of extra lesions detected would be 65 extra lesions per 100
patients. The detection of more tumor sites in patients who are known to
have one tumor localization with conventional imaging may be essential
when deciding whether to perform surgery. Octreotide scintigraphy can
be used to localize tumors, direct the choice of medical therapy, and
(expected in the near future) select patients for radiotherapy. The impact
on patient management is fourfold: Octreotide scintigraphy may detect
resectable tumors that would be unrecognized with conventional imaging
techniques; it may prevent surgery in patients whose tumors have
metastasized to a greater extent than can be detected with conventional
imaging; it may direct the choice of therapy in patients with inoperable
tumors; and in the future it may be used to select patients for radionuclide
therapy.
Detection of carcinoids is often due to the clinical signs and
symptoms of hormone overproduction. The tumor may also be
diagnosed because of local expanding growth or a chance radio-
logic or surgical finding.
When the tumor has not metastasized, or when only limited,
localized spreading to the liver has occurred, the treatment of
choice is surgery. In most patients with inoperable disease and
carcinoid syndrome, treatment with the somatostatin analog
octreotide causes a decrease of urinary 5-hydroxyindoleacetic acid
(5-HIAA) levels and alleviation of symptoms [1–4]. For those
patients who have somatostatin receptor-negative tumors, chemo-
therapy is indicated [5].
In patients with carcinoids, the localization of tumor sites with
conventional imaging means may be difficult [3]. Yet optimal
information on these sites may be important when localizing a
solitary resectable tumor and staging the extent of the tumor when
the choice of treatment depends on this information.
Large numbers of high affinity somatostatin-binding sites have
been found on carcinoid tumors [6, 7]. Over the past few years, in
vivo visualization of carcinoids using a radiolabeled somatostatin
analog, [111In-DTPA-D-Phe1]-octreotide, has been reported by
various groups. The results obtained by us and others are sum-
marized here, and the implications of the findings regarding
patient management are discussed.
Protocol of Somatostatin Receptor Imaging
The recommended dose of [111In-DTPA-D-Phe1]-octreotide to be
administered intravenously is approximately 200 MBq. With such
a dose it is possible to perform single-photon emission computed
tomography (SPECT), which may increase the sensitivity for
detecting octreotide receptor-expressing tissues. It also provides
better anatomic delineation than do planar views. Because of
bowel contamination, the use of laxatives is highly recommended
starting from the moment of injection.
Planar and SPECT images are obtained with a large field of
view gamma camera equipped with a medium-energy parallel-
hole collimator. The pulse height analyzer windows are centered
over both 111In photon peaks (172 and 245 keV) with a window
width of 20%. Data from both windows are added to the
acquisition frames. The acquisition parameters for anterior and
posterior planar images are (1) 1283 128 word matrix; (2) images
of head/neck: 300,000 preset counts (or maximum 15 minutes) at
24 hours and 15 minutes preset time (' 200,000 counts) at 48
hours after injection; (3) the remainder of the body with separate
images of the chest (including as little as possible of the liver and
spleen), upper abdomen (including liver/spleen and kidneys) and
lower abdomen: 500,000 counts (or maximum 15 minutes). For
SPECT images these parameters are (1) single head camera: (a) 60
projections, (b) 64 3 64 word matrix, (c) at least 45 to 60 seconds
acquisition time per projection; or (2) three-head camera: (a) 120
projections, (b) 64 3 64 word matrix, (c) at least 30 seconds
acquisition time per step (45 seconds for SPECT of the head). If
the time required to obtain these counts for the planar views is
short, especially when tissues with relatively high accumulationCorrespondence to: D.J. Kwekkeboom, M.D.
(e.g., abdominal organs) are included in the field of view, addi-
tional images with a longer counting time (up to 15 minutes per
planar view) are necessary to visualize lesions with low somatosta-
tin receptor density. The above-mentioned counting times per
projection for planar imaging with a single head camera imply the
need for an appropriate (long) duration of whole-body scintigra-
phy with a dual head camera (e.g., at least 40 minutes from head
to pelvis). The need for SPECT studies is inevitable, especially if
tumors are located in the abdomen and not visualized on planar
images because of overprojection by other tissues or organs.
SPECT analysis is performed with a Wiener filter on original data.
The filtered data are reconstructed with a Ramp filter.
Planar and SPECT studies are preferably performed 24 hours
after injection of the radiopharmaceutical. Planar studies after 24
and 48 hours can be carried out with the same protocol. Repeat
scintigraphy after 48 hours is especially indicated when 24-hours
scintigraphy shows accumulation in the abdomen, which may also
represent radioactive bowel content [8].
Results and Discussion
We studied a group of 52 patients diagnosed as, suspected of, or
at risk of having carcinoid tumors in whom scintigraphy with
[123I-Tyr3]-octreotide or [111In-DTPA-D-Phe1]-octreotide was
performed [9]. Accumulation of labeled octreotide at supposed
tumor sites was found during octreotide scintigraphy in 32 of 37
patients (86%) with histologically proved carcinoids, 3 of 11
patients who were thought to be surgically cured of carcinoids,
and 4 of 4 patients who were clinically suspected to have a
carcinoid [9]. In 27 patients (52%) accumulation of radioactivity
was found at previously unsuspected sites not recognized with
other imaging techniques. Histologic or radiologic evidence that
these additional sites indeed represented tumors was obtained in
10 patients for whom relevant follow-up was available. Visualiza-
tion of the carcinoids did not depend on the site of the tumor or
on the presence or absence of hormonal hypersecretion, as
measured by urinary 5-HIAA and serum a-subunit concentra-
tions. An example of somatostatin receptor imaging in a patient
with carcinoid tumors is given in Figure 1.
With octreotide scintigraphy, accumulation of radioactivity at
known tumor sites was found in 86% of our patients with
histologically proved carcinoid tumors. Comparable percentages
were found by other groups. Joseph et al. [10] reported positive
findings with octreotide scintigraphy in 26 of 32 patients with
carcinoids (81%), and additional tumor localizations were de-
Fig. 1. Somatostatin receptor imaging in a patient with carcinoid tu-
mours, 24 hours after injection of [111In-DTPA-D-Phe1]-octreotide. Right
lateral image of the head and neck (A), anterior (B) and posterior (C)
images of the thorax, and anterior (D) and posterior (E) views of the
abdomen. F. Posterior view of the lower abdomen and extremities. Note
the clear uptake of radioactivity in multiple sites, among which are skeletal
and lymph node localizations.
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tected in one-third of patients. Westlin et al. [11] detected tumor
sites with octreotide scintigraphy in 31 of 40 patients with
carcinoids (78%) and demonstrated unexpected tumor localiza-
tions in 32% of patients. Ahlman et al. [12] reported a sensitivity
of 84% for octreotide scintigraphy in 27 patients with carcinoids,
whereas unexpected tumor localizations, not recognized despite
computed tomography (CT) scanning and ultrasonography being
performed in all patients, were demonstrated in 19 patients
(70%). Verification, histologically or radiologically, of these extra
findings was obtained for 19 of 21 localizations in patients for
whom follow-up was available. Octreotide scintigraphy was the
sole imaging modality demonstrating tumor sites in four patients.
Interestingly, octreotide scintigraphy changed the clinical man-
agement in eight patients: Five patients had repeat surgery
leading to complete remission, and tumor reduction was achieved
in three patients [12].
In the group of 52 patients we studied [9], 134 lesions were
demonstrated with a combination of conventional imaging tech-
niques and octreotide scintigraphy. The detection of these lesions
with conventional imaging, octreotide scintigraphy, or a combina-
tion of these methods is presented in Table 1. The sensitivity of
the combined conventional imaging techniques that were applied
and octreotide scintigraphy were 80 of 134 lesions (60%) in 39 of
44 patients (89%) and 106 of 134 lesions (79%) in 39 of 44
patients (89%), respectively. These figures did not differ signifi-
cantly from those obtained in the group of 37 patients with
histologically proved tumors.
Comparing the results of octreotide scintigraphy and conven-
tional imaging techniques, we assumed the total number of lesions
to be the total lesions visualized by any technique. This assump-
tion was based on several grounds: (1) It applies to any imaging
technique that it can only demonstrate disease-related localiza-
tions within a certain probability. The ultimate proof, histology,
cannot always be obtained for every visualized lesion, especially if
a tumor has metastasized. (2) Limitations in the capability to
demonstrate tumors exist for all imaging techniques. In this
respect, ‘‘occult’’ tumors, such as hormonally active tumors whose
presence is certain on biochemical grounds but cannot be visual-
ized by any technique, are a good example. (3) In a number of
patients in whom octreotide scintigraphy demonstrated otherwise
unrecognized tumor localizations and in whom follow-up was
available, histologic proof was obtained afterward (see above).
In a cost-benefit analysis [13] we evaluated 15 combinations of
imaging techniques for their cost and sensitivity. The costs of
various diagnostic procedures were calculated taking into account
personnel costs, cost of materials, equipment costs, and housing
and overhead costs. Various combinations of imaging techniques
were analyzed for their cost and sensitivity in terms of the number
of lesions detected and the number of patients in whom at least
one lesion was demonstrated. It was found that octreotide scin-
tigraphy, alone or in combination with other imaging modalities,
led to the detection of more tumor sites than any combination of
conventional imaging techniques. The combination of conven-
tional imaging techniques applied in our group led to the detec-
tion of only 60% of tumor sites and failed to detect any site in 11%
of patients. The combination of octreotide scintigraphy, chest
radiography, and ultrasonography of the upper abdomen led to
the detection of lesions in all patients in whom by any imaging
means they could be demonstrated, with a sensitivity of 87% in
terms of the number of detected lesions. The calculated cost for
this imaging regimen was higher than for the combination of
conventional imaging as applied in our group. However, the
benefit was the detection of at least one lesion in 11% of patients
in whom, with conventional imaging only, no abnormalities were
found. Moreover, if the results from our patient group were
extrapolated to a group of 100 patients, the advantage in terms of
the number of extra lesions detected was 65 extra lesions per 100
patients. The detection of more tumor sites in patients who were
known to have only one tumor site by conventional imaging may
be essential when deciding whether to perform surgery. Because
of the impact on patient management, we concluded that espe-
cially because of the number of patients in whom otherwise no
tumor was demonstrated the proposed imaging strategy of oct-
reotide scintigraphy, chest radiography, and ultrasonography of
the upper abdomen justifies the greater cost compared to various
combinations of conventional imaging techniques [13].
It is important to determine whether a carcinoid has metasta-
sized when the intended treatment is surgery. When the tumor has
metastasized, it may be important to assess also the extent of
tumor spread in order to evaluate the benefit of medical treat-
ment and to anticipate or prevent future complications. When the
tumor has not metastasized or there is only limited, localized
spread to the liver, the treatment of choice is surgery. In this
respect, detection of an otherwise unrecognized solitary tumor is
crucial to patient management. In our group, as in the patient
group described by Ahlman et al. [12], solitary tumors or tumors
with limited spread were missed with conventional imaging and
detected with octreotide scintigraphy in several patients.
Of special interest in this respect is a study by Moertel et al.
[14], who performed a long-term study of 150 patients with
carcinoid tumors of the appendix. No metastases were found from
tumors , 2.0 cm in largest dimension, whereas metastases were
observed from 3 of 14 lesions $ 2 cm and 4 of 9 lesions $ 3 cm.
The authors concluded that right hemicolectomy seems justified
in young patients with tumors $ 2 cm who have a low risk of
operative morbidity or mortality. Octreotide scintigraphy in these
patients might provide useful additional information.
In patients with inoperable disease and carcinoid syndrome,
treatment with octreotide is the treatment of choice. For those
patients who have somatostatin receptor-negative tumors, chemo-
therapy is indicated [5]. In patients with carcinoid syndrome,
octreotide scintigraphy, because of its ability to demonstrate
somatostatin receptor-positive tumors, can be used to differenti-
ate between patients who are likely to respond favorably to
octreotide treatment and those who are better treated with
chemotherapy.
Lastly, the therapeutic potential of radiolabeled somatostatin
analogs should be mentioned. Somatostatin analogs with chelat-
ing groups capable of binding b-emitting radionuclides are not yet
Table 1. Comparison between lesions found with conventional imaging
techniques and octreotide scintigraphy in 52 patients.
Localization Only Conv Conv 1 Oc Only Oc Total
Extrahepatic 16 40 53 109
Liver 12 12 1 25
Conv: lesions found only with conventional imaging; Oc: lesions
found only with octreotide scintigraphy; Conv 1 Oc: lesions found with
both investigations.
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available for radiotherapy. However, radiotherapy with high dose
[111In-DTPA-D-Phe1]-octreotide (total dose 20,276 MBq) was
recently tried in a patient with a profusely metastasized neuroen-
docrine tumor [15]. This treatment resulted in reduction of the
tumor load by about 20%, probably attributable to Auger elec-
trons or conversion electrons. Despite this promising result,
b-emitting radionuclides are preferable to 111In for radiotherapy
because of their higher energies and radiation doses and their
larger particle ranges. Given the high tumor/background radioac-
tivity ratio observed in carcinoids, it may be expected that once
suitable somatostatin analogs coupled to b-emitting radionuclides
are available, effective radiotherapy will be possible.
In summary, octreotide scintigraphy can be applied to localize
tumors, to direct the choice of medical therapy, and in the near
future to select patients for radiotherapy (Fig. 2). The impact on
patient management is fourfold: Octreotide scintigraphy may
select resectable tumors that would be unrecognized with conven-
tional imaging techniques; it may prevent surgery in patients
whose tumors have metastasized to a greater extent than can be
detected with conventional imaging; it may direct the choice of
therapy in patients with inoperable tumors; and in the future it
may be used to select patients for radionuclide therapy.
Re´sume´
Chez 80 a` 90% des patients ayant une tumeur carcinoı¨de, on peut
localiser le site tumoral par la scintigraphie a` l’octre´otide [111In-
DTPA-D-Phe]. Des localisations inhabituelles sont rencontre´es
chez un a` deux tiers des patients. Dans un groupe de 52 patients,
nous avons analyse´ les re´sultats de plusieurs types de scintigra-
phies et de l’imagerie conventionnelle. La scintigraphie a`
l’octre´otide, seule ou combine´e a` d’autres me´thodes d’imagerie,
arrive a` de´tecter plus de localisations tumorales que toutes les
autres me´thodes conventionnelles, meˆme combine´es. La combi-
naison de la scintigraphie a` l’octre´otide, de la radiographie
pulmonaire et de l’e´chographie de l’abdomen sus-me´socolique
ont de´tecte´ les le´sions chez tous les patients pour lesquels
l’imagerie conventionnelle, quel que soit son type, e´tait e´galement
re´ve´latrice, avec une sensibilite´ de 87%. Les couˆts par contre
e´taient plus importants que pour les techniques conventionnelles.
Cependant, ces me´thodes avaient l’avantage de de´tecter au moins
une le´sion insoupc¸onne´e chez 11% des patients pour lesquels
l’imagerie conventionnelle n’e´tait pas parlante. Si les re´sultats de
notre groupe e´taient extrapole´s a` un groupe de 100 patients, la
de´tection des le´sions supple´mentaires serait obtenue chez 65/100
patients. Surtout, la de´tection d’autres sites tumoraux chez les
patients chez qui une seule localisation est visualise´e par des
techniques conventionnelles pourrait eˆtre de´cisive avant de de´ter-
miner si la chirurgie est indique´e ou pas. La scintigraphie a`
l’octre´otide est utile pour localiser les tumeurs, de´terminer la
meilleure tactique the´rapeutique, et, pour l’avenir, de´terminer les
patients susceptibles d’un traitement par isotopes. L’impact sur
le traitement pour le patient est quadruple: la scintigraphie a`
l’octre´otide peut se´lectionner les tumeurs re´sectables qui n’auraient
pas e´te´ reconnues avec une technique conventionnelle, elle peut
e´viter la chirurgie chez les patients ayant plus me´tastase´ que ne le
montrent les techniques conventionnelles, diriger la the´rapeutique
chez les patients non ope´rables, et enfin, dans l’avenir, se´lectionner
les patients susceptibles d’eˆtre traite´s par des isotopes.
Resumen
En 80–90% de los pacientes con carcinoides la ubicacio´n tumoral
puede ser detectada mediante escintigrafia con octreo´tido. En
Fig. 2. Scheme of how peptide receptor
scintigraphy can influence patient
management. The left arm of the scheme
depicts the information on tumor spread
that peptide scintigraphy may provide. This
information may be complementary to
conventional imaging techniques and is
anatomic in nature. Although this
information is based on specific receptor
binding, it does not specifically demonstrate
one tumor type, as other tumors and
inflammatory diseases may also be receptor-
positive. Likewise, information obtained
with conventional imaging techniques is
nonspecific in nature, demonstrating
enlargement of structures or differences in
signal intensity that may be indicative of
tumor but does not prove it. The middle
and right arm of the scheme indicate how
information on the presence or absence of
peptide receptors may influence the choice
of nonsurgical therapy.
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forma inesperada, se reportan ubicaciones adicionales en uno a
dos tercios de los pacientes. En un grupo de 52 pacientes hemos
analizado los resultados de diversas combinaciones de escinti-
grafı´a con octreo´tido y me´todos convencionales de imagenologı´a.
La escintigrafı´a con octreo´tido, so´la o en combinacio´n con otras
modalidades imagenolo´gicas, resulto´ en la deteccio´n de ma´s
ubicaciones tumorales que cualquier combinacio´n de te´cnicas
convencionales de imagenologı´a. La combinacio´n de escintigrafı´a
con octreo´tido, la radiografı´a de to´rax y la ultrasonografı´a del
abdomen superior, permitio´ la deteccio´n de lesiones en la totali-
dad de los pacientes, con una sensibilidad de 87% en te´rminos del
nu´mero de lesiones detectadas. El costo calculado para este
re´gimen de imagenologı´a fue ma´s alto que para la combinacio´n de
imagenologı´a convencional. Sin embargo, el beneficio consistio´ en
lograr la deteccio´n de por lo menos una lesio´n en 11% de los
pacientes en quienes con la imagenologı´a no se hallaron anor-
malidades. Adema´s, al extrapolar los resultados a un grupo de 100
pacientes, la ventaja en te´rminos del nu´mero de lesiones extras
detectadas fue de 65 por cada 100 pacientes. Este hallazgo de
otras ubicaciones tumorales es de importancia esencial en cuanto
a la decisio´n de emprender cirugı´a en pacientes en quienes so´lo se
ha identificado una ubicacio´n tumoral u´nica mediante imageno-
logia´ convencional. La escintigrafı´a con octreo´tido puede ser apli-
cada para localizar tumores, para orientar la escogencia de terapia
me´dica y, como se espera que ocurra en el futuro pro´ximo, para
seleccionar pacientes para radioterapia. El impacto sobre el manejo
de los pacientes es de cuatro clases: la escintigrafı´a con octreo´tido
puede seleccionar los tumores resecables que pueden permanecer
invisibles con las te´cnicas convencionales de imagenologı´a; puede
prevenir la cirugı´a en pacientes cuyos tumores ya han hecho meta´s-
tasis de mayor magnitud de la que puede ser detectada con imageno-
logı´a convencional; puede orientar la escogencia de la terapia en
pacientes con tumores inoperables; y, en el futuro, puede ser
utilizada para seleccionar pacientes para terapia con radionu´clidos.
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